An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations.

IF 5.3 2区 医学 Q1 ONCOLOGY Cancer Cell International Pub Date : 2025-02-13 DOI:10.1186/s12935-025-03677-2
Jiyuan Hu, Qi Miao, Jiayi Ren, Hongbo Su, Xianlu Zhang, Jianbin Bi, Gejun Zhang
{"title":"An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations.","authors":"Jiyuan Hu, Qi Miao, Jiayi Ren, Hongbo Su, Xianlu Zhang, Jianbin Bi, Gejun Zhang","doi":"10.1186/s12935-025-03677-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Prostate cancer is the most common male malignancy. Current diagnostic methods using single TPSA and PHI lack specificity. Some researches have created nomograms for predicting risk, but these are not easily visualized. Our study aims to find the best negative predictive value (NPV) for PHI, then build a clustering model to display prostate cancer risk categories, particularly useful for patients with PSA > 20 and be actually applied in clinical work.</p><p><strong>Method: </strong>We collected 708 patients in the training cohort and 143 in the validation cohort, divided into three groups based on their PSA levels. Next, we determined optimal and customized PHI cut-off values, calculated NPV and PPV, and selected logistic regression as the best method among several machine-learning algorithms. Subsequently, the significant variables were identified, and then a clustering algorithm was constructed. Finally, the model was validated and made available online for further clinical application.</p><p><strong>Results: </strong>The Optimal PHI cut-off lower limits for PSA > 4, PSA4-20, PSA > 20 subgroups were 23.85, 24.35, and 40.75, with upper limits of 142.9, 143, and 135.6, respectively. The clustering model of the optimal cohort for PSA > 4 and PSA 4-20 sub-groups showed a superior Silhouette coefficients of 0.433 and 0.526 than that of the customized PHI cohort (0.432, 0.452). The PSA > 20 subgroup owned the highest Silhouette coefficient of 0.572. The validation cohort showed AUC values of 0.761, 0.823, 0.833 for these 3 sub-groups, with accuracy rates of 88.81%, 90.38%, and 82.05%.</p><p><strong>Conclusion: </strong>In conclusion, our clustering model effectively categorizes patients into distinct risk groups with clear visualization and has demonstrated stability and reliability in the validation cohort, potentially aiding in early diagnosis of prostate cancer in clinical practice.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"44"},"PeriodicalIF":5.3000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827463/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03677-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aim: Prostate cancer is the most common male malignancy. Current diagnostic methods using single TPSA and PHI lack specificity. Some researches have created nomograms for predicting risk, but these are not easily visualized. Our study aims to find the best negative predictive value (NPV) for PHI, then build a clustering model to display prostate cancer risk categories, particularly useful for patients with PSA > 20 and be actually applied in clinical work.

Method: We collected 708 patients in the training cohort and 143 in the validation cohort, divided into three groups based on their PSA levels. Next, we determined optimal and customized PHI cut-off values, calculated NPV and PPV, and selected logistic regression as the best method among several machine-learning algorithms. Subsequently, the significant variables were identified, and then a clustering algorithm was constructed. Finally, the model was validated and made available online for further clinical application.

Results: The Optimal PHI cut-off lower limits for PSA > 4, PSA4-20, PSA > 20 subgroups were 23.85, 24.35, and 40.75, with upper limits of 142.9, 143, and 135.6, respectively. The clustering model of the optimal cohort for PSA > 4 and PSA 4-20 sub-groups showed a superior Silhouette coefficients of 0.433 and 0.526 than that of the customized PHI cohort (0.432, 0.452). The PSA > 20 subgroup owned the highest Silhouette coefficient of 0.572. The validation cohort showed AUC values of 0.761, 0.823, 0.833 for these 3 sub-groups, with accuracy rates of 88.81%, 90.38%, and 82.05%.

Conclusion: In conclusion, our clustering model effectively categorizes patients into distinct risk groups with clear visualization and has demonstrated stability and reliability in the validation cohort, potentially aiding in early diagnosis of prostate cancer in clinical practice.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
背景和目的:前列腺癌是最常见的男性恶性肿瘤。目前使用单一 TPSA 和 PHI 的诊断方法缺乏特异性。一些研究已创建了预测风险的提名图,但这些提名图不容易可视化。我们的研究旨在找到 PHI 的最佳阴性预测值(NPV),然后建立一个聚类模型来显示前列腺癌的风险类别,尤其适用于 PSA > 20 的患者,并实际应用于临床工作中:我们在训练队列中收集了 708 名患者,在验证队列中收集了 143 名患者,根据他们的 PSA 水平分为三组。然后,我们确定了最佳和定制的 PHI 临界值,计算了 NPV 和 PPV,并在几种机器学习算法中选择了逻辑回归作为最佳方法。随后,我们确定了重要变量,并构建了聚类算法。最后,对模型进行了验证,并在网上公布,供临床进一步应用:PSA>4、PSA4-20、PSA>20亚组的最佳PHI临界值下限分别为23.85、24.35和40.75,上限分别为142.9、143和135.6。PSA > 4 和 PSA 4-20 亚组的最佳队列聚类模型的 Silhouette 系数分别为 0.433 和 0.526,优于定制 PHI 队列的 Silhouette 系数(0.432、0.452)。PSA > 20 亚组的剪影系数最高,为 0.572。验证队列显示,这 3 个亚组的 AUC 值分别为 0.761、0.823 和 0.833,准确率分别为 88.81%、90.38% 和 82.05%:总之,我们的聚类模型能有效地将患者划分为不同的风险组别,清晰可视,并在验证组别中表现出稳定性和可靠性,有望在临床实践中帮助早期诊断前列腺癌。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
10.90
自引率
1.70%
发文量
360
审稿时长
1 months
期刊介绍: Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.
期刊最新文献
Comprehensive network pharmacology and experimental study to investigate the effect and mechanism of solasonine on breast carcinoma treatment. Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization. Mechanistic insights of lenvatinib: enhancing cisplatin sensitivity, inducing apoptosis, and suppressing metastasis in bladder cancer cells through EGFR/ERK/P38/NF-κB signaling inactivation. The role of mitochondrial biogenesis, mitochondrial dynamics and mitophagy in gastrointestinal tumors. Overexpressed NEK2 contributes to progression and cisplatin resistance through activating the Wnt/β-catenin signaling pathway in cervical cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1